Spike-and-wave

Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020

Retrieved on: 
Tuesday, December 1, 2020
Health, Clinical medicine, Medicine, Syndromes, Neurological disorders, Lennox–Gastaut syndrome, Epilepsy, Lennox, LGS, Seizure, Epilepsy syndromes, Spike-and-wave

Zogenix will also host a virtual scientific exhibition room and sponsor a continuing medical education (CME) symposium during AES 2020.

Key Points: 
  • Zogenix will also host a virtual scientific exhibition room and sponsor a continuing medical education (CME) symposium during AES 2020.
  • Lennox-Gastaut Syndrome (LGS) is a rare and devastating lifelong childhood-onset epilepsy that can arise from multiple different causes.
  • Although rare, it one of the most common forms of genetic epilepsy.
  • FINTEPLA is also in development for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare and devastating childhood-onset epilepsy.

The lennox-gastaut syndrome treatment market will register a CAGR of almost 5% by 2023

Retrieved on: 
Tuesday, April 16, 2019
Lennox–Gastaut syndrome, Lennox, LGS, Health, Medicine, Clinical medicine, Anticonvulsants, Seizure types, Spike-and-wave, Epilepsy syndromes

As a result, a rising number of patients with these risk factors will drive the LGS treatment market growth during the forecast period.

Key Points: 
  • As a result, a rising number of patients with these risk factors will drive the LGS treatment market growth during the forecast period.
  • Analysts have predicted that the lennox-gastaut syndrome treatment market will register a CAGR of almost 5% by 2023.
  • One of the growth drivers of the global lennox-gastaut syndrome treatment market is the rising population with risk factors for LGS.
  • One of the challenges in the growth of global lennox-gastaut syndrome treatment market is the side effects associated with available treatment.